Key facts
- This page summarizes Christopher Posner's Form 4 filing for Cara Therapeutics, Inc. (TVRD).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2025, 16:59.
Christopher Posner - 28 Feb 2025 Form 4 Insider Report for Cara Therapeutics, Inc. (TVRD)
- Reporting relationship
- PRESIDENT AND CEO, Director
- Issuer ticker
- TVRD
- Reported as of
- 28 Feb 2025
- Net transaction value
- -$2,769
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2025, 16:59:22 UTC
- Prior SEC filing
- 06 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darren DeStefano, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher Posner filed Form 4 for Cara Therapeutics, Inc. (TVRD) on 04 Mar 2025.
Change
- Previous filing in this sequence was filed on 06 Feb 2025.
- Current net transaction value: -$2,769.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CARA
transaction
Common Stock
Sale
- Transaction value
- $2,769
- Shares
- -583
- Change %
- -4.3%
- Price
- $4.75
- Shares after
- 13,109
- Date
- 28 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
Footnote F2
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.